Story thread · 2 reports / 2 sources
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
financialpost.com · 7h · first report
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded […]
The coverage
- Arbutus gains on plans to buy back 46M shares in tender offer
seekingalpha.com · 1h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.